Pharmaceutical Co. Settles SAC Lawsuit

Nov 10 2010 | 5:08am ET

The long-running, often nasty, sometime vexatious legal battle between SAC Capital Advisors and Canadian pharmaceutical company Biovail is finally at an end.

Valeant Pharmaceuticals, which merged with Biovail in June, agreed to pay US$10 million to SAC to settle a countersuit filed by the hedge fund in February. Biovail's own lawsuit against SAC—which the Stamford, Conn.-based firm called "vexatious"—was dismissed last year.

Another lawsuit against SAC, filed by Biovail shareholders, met the same fate.

Valeant's announcement of the settlement, which came alongside its quarterly loss announcement, also included the closest thing to an apology that SAC is likely to get.

"The initiation of litigation against SAC and others in 2006 by Biovail's management at the time was regrettable," CEO J. Michael Pearson said. "We would like to put this incident behind us."

Valeant also settled a lawsuit filed by Gradient Analytics, a research firm and one of SAC's co-defendants in the Biovail litigation. SAC and Gradient were accused of conspiring to drive the company's stock price down.

The US$10 million will cover a "portion" of SAC's legal expenses in the case. Still, the hedge fund said it was "pleased with this outcome."

"SAC continues to believe that Biovail's lawsuit and the media campaign that accompanied it were designed to distract critics from the company's own conduct," the firm said.


In Depth

Q&A: Star Mountain's Brett Hickey On Investing In 'The Growth Engine Of America'

Sep 22 2017 | 5:06pm ET

Lower middle-market companies form the economic fabric of the nation, but they can...

Lifestyle

CFA Institute To Add Computer Science To Exam Curriculum

May 24 2017 | 9:25pm ET

Starting in 2019, financial industry executives sitting for the coveted Chartered...

Guest Contributor

Don’t Overlook These 6 Hybrid Cloud Concerns

Sep 14 2017 | 6:27pm ET

Cloud-based technology solutions have made tremendous inroads into the alternative...

 

From the current issue of